Cryoport, INC Form 4 insider transactions

Cryoport, Inc.'s Chief Digital and Tech Officer, Edward J. Zecchini, exercised stock options and subsequently sold a portion of the acquired shares on June 10, 2025.

Cryoport, Inc. Director Daniel M. Hancock was granted 23,214 restricted stock rights and 41,098 stock options, increasing his beneficial ownership and aligning his interests with the company's long-term performance.

A recent SEC Form 4 filing reveals Cryoport, Inc. Director Ramkumar Mandalam received substantial equity grants while also executing a sale of common stock.

Cryoport, Inc. Director Robert J. Hariri has reported the acquisition of 23,214 restricted stock rights and 41,098 stock options, increasing his beneficial ownership in the company.

Cryoport, Inc. Director Linda Baddour was granted 23,214 restricted stock units and options to purchase 41,098 shares of common stock as part of her compensation.

Cryoport, Inc.'s President and CEO, Jerrell Shelton, exercised 50,000 stock options at $5 per share, increasing his direct beneficial ownership of common stock to 862,419 shares.

Cryoport, Inc.'s President and CEO, Jerrell Shelton, filed an amended Form 4 with the SEC to correct an error, clarifying that a reported transaction was a cash exercise of stock options, not a disposition of common stock.

Cryoport, Inc. President and CEO Jerrell Shelton exercised 50,000 stock options at $5 per share, increasing his direct beneficial ownership of common stock to 812,419 shares.

Cryoport Director Robert J. Hariri reported the sale of 12,500 shares of Cryoport common stock at $6.10 per share on May 28, 2025, reducing his direct beneficial ownership to 8,061 shares.

Mark W. Sawicki, Chief Scientific Officer of Cryoport, Inc., reported the sale of 1,349 shares of common stock on March 24, 2025, to cover taxes due upon vesting of restricted stock rights.

Cryoport's CFO, Robert Stefanovich, sold 1,070 shares of common stock on March 24, 2025, to cover tax obligations arising from the vesting of restricted stock rights.

Cryoport's CEO, Jerrell Shelton, sold 2,980 shares of common stock on March 24, 2025, to cover tax obligations related to vesting restricted stock rights.

Edward Zecchini, Chief Digital and Tech Officer of Cryoport, reports acquisition and disposal of company stock and stock options.

Cryoport's CFO, Robert Stefanovich, reports acquisition and disposal of company stock and stock options.

Mark Sawicki, Chief Scientific Officer of Cryoport, Inc., reports acquisition of stock options and restricted stock rights, as well as the sale of common stock to cover taxes.

Cryoport's CEO, Jerrell Shelton, reports acquisition and disposal of company stock and stock options.

Mark Sawicki, Chief Scientific Officer of Cryoport, Inc., reports the conversion of restricted stock rights and subsequent sale of shares to cover taxes.

Cryoport's CEO, Jerrell Shelton, reports the conversion of restricted stock rights and the sale of shares to cover taxes.

Robert Stefanovich, CFO of Cryoport, Inc., reports the conversion of restricted stock rights and subsequent sale of shares to cover taxes.

Cryoport's Chief Financial Officer, Robert Stefanovich, exercised stock options to acquire 53,334 shares of common stock at $4.80 per share.

Cryoport director Ramkumar Mandalam exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Cryoport director Robert J. Hariri sold 2,500 shares of common stock at an average price of $6.48 on November 21, 2024.

Cryoport's CEO, Jerrell Shelton, executed multiple stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

Cryoport's CEO, Jerrell Shelton, exercised stock options and sold shares over three days, as part of a pre-arranged trading plan.

Director Robert J. Hariri sold 1,000 shares of Cryoport, Inc. (CYRX) at a price of $9.465 on August 19, 2024.

Robert J. Hariri, a director at Cryoport, Inc., sold 2,000 shares of common stock in two transactions during August 2024.

Director Ramkumar Mandalam exercised stock options and sold shares of Cryoport, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Director Ramkumar Mandalam reports receiving a grant of restricted stock rights and an option award for Cryoport, Inc.

Director Linda Baddour reports acquisition of restricted stock rights and stock options in Cryoport, Inc.

Director Robert J. Hariri reports acquisition of common stock and options in Cryoport, Inc.